D. Jones

发表

Cytotoxic T lymphocyte antigen‐4 (CTLA‐4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis

P. Donaldson, A. Czaja, K. Agarwal, 2000, Hepatology.

Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes

D. Jones, M. Bassendine, O. James, 1997, Hepatology.

Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis

David C. Jones, A. Burt, D. Jones, 2002, Gut.

T-cell autoimmunity in primary biliary cirrhosis.

David C. Jones, D. Jones, 1996, Clinical science.

Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis

J. Kirby, D. Jones, S. Yeaman, 2000, Immunological reviews.

Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis: A mouse model of primary biliary cirrhosis

David C. Jones, J. Kirby, D. Jones, 1999, Hepatology.

Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort

N. Bhala, J. Newton, D. Jones, 2005, Gut.

Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study.

David C. Jones, D. Jones, O. James, 2004, QJM : monthly journal of the Association of Physicians.

Chemokine receptor 5 and primary biliary cirrhosis: a two‐centre genetic association study

A. Floreani, P. Donaldson, K. Agarwal, 2004, Liver international : official journal of the International Association for the Study of the Liver.

Pathogenesis of primary biliary cirrhosis

D. Jones, David Jones, 2008, Postgraduate Medical Journal.

Primary biliary cirrhosis: clinical and associated autoimmune features and natural history.

David C. Jones, D. Jones, M. Bassendine, 1998, Clinics in liver disease.

CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis.

S. Pearce, K. Agarwal, B. Vaidya, 2000, Journal of hepatology.

Editorial: scoring systems in primary biliary cholangitis – time to make a move

G. Mells, D. Jones, 2017, Alimentary pharmacology & therapeutics.

Cancer risk in primary biliary cirrhosis: a study in northern England

D. Howel, D. Jones, O. James, 1999, Gut.

Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation

D. Jones, L. Powell, A. Clouston, 1999 .

Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation.

D. Jones, L. Powell, A. Clouston, 1998, Gut.

Primary biliary cirrhosis

David C. Jones, D. Jones, M. Bassendine, 1989, Autoimmunity.

University of Birmingham A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

A. Floreani, K. Kowdley, M. Trauner, 2016 .

Familial primary biliary cirrhosis reassessed: a geographically-based population study.

David C. Jones, D. Jones, M. Bassendine, 1999, Journal of hepatology.

No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis.

David C. Jones, J. Grove, D. Jones, 1998, Journal of hepatology.

Editorial: fenofibrate as second‐line therapy in high risk PBC – more answers or more questions?

D. Jones, B. E Hansen, 2016, Alimentary pharmacology & therapeutics.

Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo‐controlled, cross‐over trial

D. Jones, O. James, D. Burke, 2003, Alimentary pharmacology & therapeutics.

Fetal microchimerism: an aetiological factor in primary biliary cirrhosis?

D. Jones, 2000, Journal of hepatology.

The immunology of primary biliary cirrhosis: the end of the beginning?

J. Kirby, D. Jones, J. Palmer, 2002, Clinical and experimental immunology.

CD4+ T cell subsets defined by isoforms of CD45 in primary biliary cirrhosis

D. Jones, M. Bassendine, G. Spickett, 1995, Clinical and experimental immunology.

Osteoporosis in primary biliary cirrhosis revisited

J. Newton, D. Jones, M. Bassendine, 2001, Gut.

Painless Small Bowel Ischemia Presenting With Diarrhea and Weight Loss

D. Jones, I. Cobden, J. Barton, 1998, American Journal of Gastroenterology.

Secretory autoantibodies in primary biliary cirrhosis (PBC)

J. Kirby, D. Jones, S. Yeaman, 2000, Clinical and experimental immunology.

The basis of autoimmunity: an overview.

D. Jones, A. Diamond, David E.J. Jones, 1995, Bailliere's clinical endocrinology and metabolism.

Painless small bowel ischemia presenting with diarrhea and weight loss.

D. Jones, I. Cobden, J. Barton, 1998 .

HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility

P. Donaldson, K. Agarwal, D. Jones, 2001, Gut.

Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use.

D. Jones, O. James, M. Prince, 2000, Journal of hepatology.

Autoantigens in primary biliary cirrhosis

D. Jones, David Jones, 2000, Journal of clinical pathology.

PTU-106 Patient Impact of Inflammation in Primary Biliary Cirrhosis (Pbc): Inflammatory Cytokine Levels are Elevated but Unrelated to Fatigue Severity

D. Jones, G. Pells, S. Ducker, 2013, Gut.

Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis

A. Jacoby, J. Newton, D. Buck, 2005, Gut.

The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

J. Neuberger, D. Stocken, R. Sandford, 2016, Alimentary pharmacology & therapeutics.

POISE: A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England Journal of Medicine 2016, 375, 631-643

J. Reguła, F. Nevens, A. Floreani, 2016 .

T cell responses to natural human proteins in primary biliary cirrhosis

D. Jones, S. Yeaman, M. Bassendine, 1997, Clinical and experimental immunology.

The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study

F. Lammert, M. Krawczyk, C. Corpechot, 2016, Alimentary pharmacology & therapeutics.

T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function.

D. Jones, S. Yeaman, M. Bassendine, 1997, Gut.

Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis.

J. Newton, J. Grove, D. Jones, 1999, Journal of hepatology.

Primary biliary cirrhosis is associated with falls and significant fall related injury.

J. Newton, D. Jones, S. Kerr, 2010, QJM : monthly journal of the Association of Physicians.

Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels

J. Hajnal, A. Oatridge, J. Allsop, 2004, Gut.

Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis.

D. Jones, S. Yeaman, M. Bassendine, 1997, Seminars in liver disease.

Grip strength and subjective fatigue in patients with primary biliary cirrhosis.

D. Jones, O. James, J. Goldblatt, 2001, JAMA.

Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging

A. Waldman, R. Chapman, J. Fitzpatrick, 2016, Alimentary pharmacology & therapeutics.

Familial primary biliary cirrhosis and autoimmune cholangitis.

A. Floreani, K. Agarwal, A. Burt, 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Fatigue in primary biliary cirrhosis

J. Hajnal, A. Oatridge, H. Thomas, 2005, Gut.

Primary biliary cirrhosis.

D. Jones, M. Bassendine, 1960, Journal of internal medicine.

Experimental autoimmune cholangitis: a mouse model of immune-mediated cholangiopathy.

J. Kirby, A. Burt, D. Jones, 2000, Liver.

PTH-103 Clinician Confidence in Stratifying Risk in Primary Biliary Cirrhosis - A UK-PBC Survey

D. Jones, L. Vale, M. Corrigan, 2016 .

Genetic susceptibility to primary biliary cirrhosis.

David C. Jones, K. Agarwal, D. Jones, 1999, European journal of gastroenterology & hepatology.

The interrelationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

Eld, J. Neuberger, D. Stocken, 2016 .

Presentation and mortality of primary biliary cirrhosis in older patients.

J. Newton, A. Burt, D. Jones, 2000, Age and ageing.

OP01 WHO DIES FROM ALCOHOLIC LIVER DISEASE AND WHERE ARE POSSIBLE THERAPEUTIC INTERVENTIONS MISSED? AN ANALYSIS OF 755 DEATHS IN A HEALTH COMMUNITY

R. Chapman, A. Burroughs, K. Kowdley, 2011 .

The CLO test in the UK: inappropriate reading and missed results.

J. Barton, D. Jones, J. S. Osborne, 1999, European journal of gastroenterology & hepatology.

University of Birmingham The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

J. Neuberger, D. Stocken, R. Sandford, 2016 .

OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC

R. Chapman, A. Burroughs, D. Shapiro, 2011, Gut.

PTU-304 Cost-effectiveness of current therapies in primary biliary cirrhosis: a systematic review of economic evidence

D. Jones, G. Pells, L. Vale, 2015 .